-
Neuralstem’s $19.6M offering takes ALS bid through phase II
In a front-page feature story, BioWorld Today’s Randy Osborne talks to Neuralstem’s President and CEO, Richard Garr, about the recent financing announcement and how, upon expected closing, it will impact current and upcoming clinical trials, including NSI-566/ALS Phase II, NSI-189/MDD
Phase II filing, and FDA-approved NSI-566/cSCI Phase I. The article also explores the company’s novel approach to cell therapy and the mechanisms of action by NSI-566 for different indications, such as building new circuitry to “bridge the gap” in spinal cord injury.
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.